Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Biotech
AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer
AbbVie is paying $700 million for a next-generation rival to J&J's Tecvayli, positioning the Big Pharma to advance a new option for multiple myeloma.
Nick Paul Taylor
Jul 10, 2025 9:01am
Biotech shares first data for in vivo CAR-T that attracted AZ
Jul 7, 2025 2:27pm
Pfizer-backed CellCentric secures $120M for ph. 3 myeloma trial
May 19, 2025 9:25am
C4T halts BRAF degrader work to save cash for cemsidomide
May 7, 2025 7:00am
British biotech CellCentric expands to Boston, plans hiring push
Apr 2, 2025 1:53pm
Genmab axes anti-CD38 antibody after losing J&J support
Mar 10, 2025 2:13pm
